SETD8/KMT5A

SETD8, also known as KMT5A, is the sole mammalian lysine methyltransferase that monomethylates histone H4 at lysine 20 (H4K20me1)^[1][2]. This modification regulates chromatin compaction, transcription of oncogenes and tumor suppressors, and DNA double-strand break repair pathway choice^[3][2]. SETD8 additionally methylates non-histone proteins including p53 and proliferating cell nuclear antigen (PCNA), modulating cell cycle progression, apoptosis, and DNA replication^[1][4][5]. In cancer models, SETD8 overexpression correlates with enhanced proliferation, invasion, and metastasis, as observed in hepatocellular carcinoma, triple-negative breast cancer, and neuroblastoma^[6][7][4]. Mechanistically, SETD8-mediated methylation of SNIP1 and p53 attenuates tumor suppressive signaling, promoting oncogenesis and chemoresistance^[7][5]. Compared with other lysine methyltransferases, SETD8 uniquely targets H4K20 and specific non-histone lysines, establishing functional specificity over isoforms^[3][1]. Pharmacological inhibition using selective compounds such as UNC0379, SGSS05-NS3, and MS2928 restores p53 activity, suppresses tumor growth, and enhances cytotoxic T-cell responses in xenograft and preclinical models^[4][8][9]. These inhibitors exhibit isoform selectivity, covalent binding, and robust cellular efficacy, enabling their use in functional studies of SETD8-dependent pathways and therapeutic explorations^[9][8]. Overall, SETD8 is a critical epigenetic regulator of chromatin state, DNA repair, and tumorigenic signaling, making it a validated target for experimental and preclinical cancer research^[6][3][1].